ClinicalTrials.gg
AvailableNCT07119775Updated Aug 13, 2025

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

An expanded access record providing Tideglusib in Congenital Myotonic Dystrophy, sponsored by AMO Pharma Limited. Available. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by AMO Pharma Limited · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
01

Study summary

This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.

02

Conditions studied

  • Congenital Myotonic Dystrophy

Browse trials for

Keywords

  • Tideglusib
  • Congenital Myotonic Dystrophy
  • Myotonic Dystrophy
  • Dystrophia Myotonica
  • Myotonia Atrophica
  • Myotonia Dystrophica
  • Myotonic Dystrophy, Congenital Steinert Disease
  • Steinert Myotonic Dystrophy
  • Steinert's Disease
03

In context

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Lead sponsor

AMO Pharma Limited is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
This record does not list eligibility criteria. Contact the study team before assuming you do or do not qualify.
05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07119775
Lead sponsor
AMO Pharma Limited
Responsible party
Sponsor
First posted
Aug 13, 2025
Last update
Aug 13, 2025

Study contacts

Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM
Contact
h.graystephens@amo-pharma.com
+44 (0)1270 270010
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion